# Appendix B: Key Companies & What They Do

**Purpose**: A reference table of the most important companies shaping biomedical innovation, organized by sector. For each: what they actually do, why they matter, approximate scale, and what to watch for. Updated through early 2026.

---

## B.1 Big Pharma — The Top 20

| Company | HQ | 2024 Revenue | Key Franchises | What to Watch |
|---------|-----|-------------|----------------|---------------|
| **Eli Lilly** | Indianapolis | ~$45B | GLP-1 (tirzepatide/Mounjaro), Alzheimer's (donanemab), oncology | Became world's most valuable pharma company on GLP-1 wave; donanemab approval dynamics |
| **Novo Nordisk** | Bagsværd, DK | ~$42B | GLP-1 (semaglutide/Ozempic/Wegovy), insulin, rare blood | Obesity franchise transforming the company; CagriSema next-gen; supply constraints |
| **Roche** | Basel, CH | ~$62B (pharma+diagnostics) | Oncology (atezolizumab), ophthalmology (faricimab), diagnostics | Pharma-diagnostics integration; Genentech R&D engine; biosimilar erosion of Herceptin/Avastin |
| **Johnson & Johnson** | New Brunswick | ~$54B (Innovative Medicine) | Immunology (Tremfya/guselkumab), oncology (Darzalex, Carvykti CAR-T) | Spun off consumer health (Kenvue); pure pharma/medtech focus |
| **AbbVie** | N. Chicago | ~$56B | Immunology (Humira→Skyrizi/Rinvoq), oncology, neuroscience | Post-Humira cliff management; Skyrizi/Rinvoq ramp; Cerevel acquisition ($8.7B) for neuro |
| **Pfizer** | New York | ~$59B | COVID franchise declining; oncology (Seagen $43B acquisition), rare disease | Seagen integration; Padcev/ADC pipeline; managing post-COVID revenue cliff |
| **Merck & Co.** | Rahway | ~$64B | Oncology (Keytruda: $25B+), vaccines (Gardasil), cardiometabolic | Keytruda patent cliff ~2028; massive M&A to diversify; China biosimilar threat |
| **AstraZeneca** | Cambridge, UK | ~$50B | Oncology (Tagrisso, Enhertu), rare disease (Alexion), respiratory | Rapid growth from oncology; Daiichi Sankyo ADC partnership; Alexion integration |
| **Novartis** | Basel, CH | ~$50B | Cardiovascular (Entresto, Leqvio), immunology, cell/gene therapy (Kymriah) | Sandoz spinoff complete; focused innovative medicines; radioligand therapy platform |
| **Bristol-Myers Squibb** | Princeton | ~$45B | Oncology (Opdivo, Revlimid), hematology, cardiovascular (Camzyos) | Multi-product LOE wave; CAR-T (Abecma, Breyanzi); Karuna acquisition (schizophrenia) |
| **GSK** | London | ~$38B | Vaccines (Shingrix, Arexvy/RSV), HIV (ViiV), oncology | Respiratory pivot; Haleon consumer spinoff; oncology build-out |
| **Sanofi** | Paris | ~$46B | Immunology (Dupixent: $13B+), vaccines, rare disease | Dupixent growth across indications; Inhibrx acquisition; rare blood |
| **Amgen** | Thousand Oaks | ~$33B | Inflammation (Repatha, Otezla), oncology, rare disease | MariTide (obesity bispecific); Horizon acquisition ($27.8B); biosimilars portfolio |
| **Regeneron** | Tarrytown | ~$14B | Dupixent (co-marketed w/ Sanofi), Eylea, oncology (Libtayo) | VelociSuite technology platform; genetics-driven drug discovery (RGC partnership) |
| **Gilead** | Foster City | ~$27B | HIV (Biktarvy, lenacapavir), oncology (Trodelvy), inflammation | Lenacapavir for PrEP (game-changer); hepatitis franchise declining; oncology growth |
| **Takeda** | Tokyo/Cambridge | ~$30B | GI (Entyvio), rare disease, neuroscience, oncology | Largest Japanese pharma; pipeline refresh post-Shire acquisition |
| **Bayer** | Leverkusen, DE | ~$25B (pharma) | Cardiovascular (Xarelto declining), oncology, cell/gene therapy | Restructuring; Monsanto litigation overhang; pipeline rebuild |
| **Boehringer Ingelheim** | Ingelheim, DE | ~$28B | Respiratory (Jardiance w/ Lilly), immunology, animal health | Largest private pharma; surlatinib; long-term R&D perspective |
| **Daiichi Sankyo** | Tokyo | ~$16B | ADC platform (Enhertu with AstraZeneca, Dato-DXd) | ADC franchise could be transformational; multiple next-gen payloads |
| **Biogen** | Cambridge | ~$10B | Neurodegeneration (Leqembi w/ Eisai), rare disease, biosimilars | Lecanemab uptake; SMA franchise (Spinraza declining to gene therapy); strategic pivot |

---

## B.2 TechBio & AI-Native Drug Discovery

| Company | Founded | Funding/Valuation | What They Do | Pipeline Status |
|---------|---------|------------------|-------------|----------------|
| **Recursion Pharmaceuticals** | 2013 | Public (~$3B mkt cap); acquired Exscientia ($688M, 2025) | AI + automated biology for drug discovery; phenomic screening at massive scale | REC-994 (cerebral cavernous malformations) Phase 2; multiple preclinical |
| **Isomorphic Labs** | 2021 | DeepMind spinout; Alphabet-backed | AlphaFold-derived drug design; ~$3B Lilly+Novartis deals | Preclinical; structure-based design |
| **Insilico Medicine** | 2014 | ~$700M raised | AI-designed molecules end-to-end; INS018_055 first AI-originated drug in Phase 2 | INS018_055 (IPF) Phase 2; multiple Phase 1 |
| **Relay Therapeutics** | 2016 | Public (~$2B mkt cap) | Dynamo platform: motion-based drug design using MD simulations + ML | RLY-2608 (PI3Kα mutant-selective) Phase 1 |
| **Generate Biomedicines** | 2020 | ~$700M raised (Flagship) | Generative biology for protein therapeutic design | Preclinical biologics |
| **Absci Corporation** | 2011 | Public | Generative AI for antibody design; zero-shot de novo antibodies | Preclinical; Merck/AstraZeneca partnerships |
| **Tempus AI** | 2015 | Public (~$8B mkt cap) | Clinical data + genomics platform; real-world evidence for drug development + clinical decisions | Diagnostic products; pharma data partnerships; AI clinical tools |
| **Owkin** | 2016 | ~$300M raised | Federated learning on hospital pathology data; biomarker discovery | Diagnostic AI products; pharma partnerships with Sanofi |
| **XtalPi** | 2014 | ~$1B raised | Crystal structure prediction + AI for small molecule optimization | Pharma partnerships; preclinical |
| **Charm Therapeutics** | 2021 | ~$75M raised | Protein-ligand co-folding (DragonFold) for structure-based drug design | Preclinical |
| **Cradle** | 2021 | ~$73M raised | ML-guided protein engineering; generative models for biologics optimization | Platform partnerships |
| **Profluent Bio** | 2022 | ~$35M raised | Protein language models; designed OpenCRISPR-1 (first AI-designed gene editor used in human cells) | OpenCRISPR-1 demonstrated in human cells |

---

## B.3 Gene Therapy, Cell Therapy & Genetic Medicines

| Company | Focus | Key Products/Platform | Status |
|---------|-------|-----------------------|--------|
| **Vertex Pharmaceuticals** | CF, gene editing, pain, diabetes | Casgevy (first CRISPR therapy, with CRISPR Tx); VX-880 (islet cell therapy for T1D); suzetrigine (non-opioid pain) | Multiple approved; broad pipeline |
| **CRISPR Therapeutics** | Gene editing (CRISPR) | Casgevy for SCD/TDT (w/ Vertex); CTX110 allogeneic CAR-T | First approved CRISPR therapy |
| **Editas Medicine** | Gene editing (CRISPR) | EDIT-301 (SCD); EDIT-101 (LCA10); in vivo editing | Phase 1/2 |
| **Intellia Therapeutics** | In vivo CRISPR editing | NTLA-2001 (ATTR, first in vivo CRISPR in humans); NTLA-2002 (HAE) | Phase 3 (ATTR); Phase 2 (HAE) |
| **Beam Therapeutics** | Base editing | BEAM-101 (SCD); BEAM-302 (alpha-1 antitrypsin deficiency) | Phase 1/2; Pfizer partnership |
| **Prime Medicine** | Prime editing | In vivo and ex vivo programs across genetic diseases | Preclinical; most precise editing modality |
| **Bluebird Bio** | Lentiviral gene therapy | Lyfgenia (SCD); Skysona (ALD); Zynteglo (TDT) | 3 approved; financial struggles |
| **Moderna** | mRNA therapeutics | COVID vaccine; RSV vaccine; ~45 mRNA development candidates | Expanding beyond COVID; cancer vaccines (individualized neoantigen) with Merck |
| **BioNTech** | mRNA + immunotherapy | COVID vaccine; mRNA cancer immunotherapies; next-gen CAR-T (BNT211) | Broad immuno-oncology pipeline |
| **Alnylam Pharmaceuticals** | RNA interference (siRNA) | Onpattro (patisiran), Amvuttra (vutrisiran), Leqvio (inclisiran, licensed to Novartis) | 5 approved RNAi therapies; hepatocyte delivery solved; expanding beyond liver |
| **Ionis Pharmaceuticals** | Antisense oligonucleotides (ASO) | Spinraza (SMA), eplontersen (ATTR), tofersen (SOD1-ALS) | 6+ approved ASOs; >40 clinical programs |
| **Ultragenyx** | Rare genetic diseases | Gene therapies for hemophilia, mucopolysaccharidoses, GSD; biologics | Multiple approved rare disease products |
| **BioMarin** | Rare disease + gene therapy | Roctavian (hemophilia A gene therapy); Vimizim, Naglazyme (enzyme replacement) | Pioneer in rare disease; gene therapy commercial challenges |
| **Legend Biotech** | CAR-T cell therapy | Carvykti (cilta-cel; with J&J) for multiple myeloma | Potential best-in-class BCMA CAR-T |
| **Arctus Therapeutics** | Self-amplifying mRNA (saRNA) | ARCT-154 (COVID saRNA vaccine, approved in Japan); oncology programs | Self-amplifying RNA pioneer |

---

## B.4 Diagnostics & Early Detection

| Company | Focus | Key Technology | Stage |
|---------|-------|---------------|-------|
| **GRAIL (Illumina)** | Multi-cancer early detection | Galleri: cfDNA methylation test detecting 50+ cancers from blood | Commercial; PATHFINDER 2 trial: 1.3% cancer signal detected rate; NHS pilot (140K participants) |
| **Guardant Health** | Liquid biopsy for cancer | Shield (CRC screening from blood, FDA-approved 2024); Guardant360 (companion diagnostic) | Multiple approved products; Shield specificity 83%, sensitivity varies |
| **Exact Sciences** | Cancer screening | Cologuard (stool DNA for CRC); OncoExTra (comprehensive genomic profiling) | Cologuard widely adopted; expanding beyond CRC |
| **Olink Proteomics (Thermo Fisher)** | Proteomics at scale | Proximity Extension Assay (PEA); Explore 3072 (measures 3,000+ proteins from 1μL) | Acquired by Thermo Fisher ($3.1B); UK Biobank proteomics partner |
| **SomaLogic (Standard BioTools)** | Proteomics platform | SomaScan: 11,000+ protein targets from single sample; aptamer-based | Merged with Standard BioTools; large-scale epidemiological studies |
| **Neko Health** | Whole-body screening | Full-body scan with multiple modalities + AI; clinic-based | Operating in Sweden; expanding to UK; co-founded by Spotify's Daniel Ek |
| **Prenuvo** | Full-body MRI screening | Non-contrast whole-body MRI with AI analysis | Commercial in US/Canada; $2,499 per scan; asymptomatic screening |
| **Nightingale Health** | NMR metabolomics | 250+ biomarkers from single blood sample; NMR-based; UK Biobank (500K samples) | Commercial; population-scale metabolomics |
| **Freenome** | Multi-omics liquid biopsy | Multiomics (cfDNA, proteins, methylation) for CRC screening | Phase 3 (PREEMPT CRC study) |
| **Illumina** | Sequencing | NovaSeq X Plus (~$200 genomes); DRAGEN analysis | Market leader; >90% sequencing market share |
| **Pacific Biosciences** | Long-read sequencing | Revio HiFi (99.9% accuracy, ~$1K genome); Onso short-read | HiFi revolutionizing structural variant detection |
| **Oxford Nanopore** | Nanopore sequencing | PromethION (ultra-long reads, real-time); MinION (portable) | Field deployment; real-time pathogen surveillance; direct RNA sequencing |
| **10x Genomics** | Single-cell multiomics | Chromium (scRNA-seq), Visium/Xenium (spatial transcriptomics) | Spatial transcriptomics rapidly expanding; patent disputes with NanoString |

---

## B.5 Platform Technology Companies

| Company | Technology | What It Enables | Key Metric |
|---------|-----------|-----------------|------------|
| **Cellarity** | Cell-centric drug discovery | Shifts from single-target to cell-behavior-level drug discovery using single-cell genomics + ML | Founded by Aviv Regev; Flagship Pioneering |
| **Insitro** | ML + high-throughput biology | iPSC disease models + machine learning for target/biomarker discovery | Partnerships: BMS, Gilead; $700M+ raised |
| **Phenomic AI** | AI-powered phenotypic screening | High-content imaging + ML for drug mechanism discovery | Founded by Anne Bhatt (ex-Recursion) |
| **Bruker** | Mass spectrometry, cryo-EM, NMR | timsTOF Ultra 2 (4D proteomics); cryo-EM instruments | Acquired NanoString; leading structural biology tools |
| **Thermo Fisher Scientific** | Everything (sequencing, mass spec, reagents, instruments) | Ion Torrent sequencing; Orbitrap mass spec; Olink proteomics; cell culture; lab consumables | $42B revenue; "picks and shovels" of biotech |
| **Twist Bioscience** | Synthetic biology / DNA synthesis | High-throughput DNA synthesis on silicon; antibody libraries; NGS target enrichment | $260M revenue; enabling synthetic biology at scale |
| **Ginkgo Bioworks** | Cell programming | Automated strain engineering; biosecurity (Concentric); synthetic biology platform | $350M+ revenue; partnerships across sectors |
| **Benchling** | Lab informatics | Cloud R&D platform for biotech (ELN, LIMS, registry) | Used by 200K+ scientists; $6.1B valuation |
| **Emerald Cloud Lab / Strateos** | Cloud laboratories | Fully remote-operated automated labs; API-driven experiments | Enabling "labless" biotech companies |
| **Schrödinger** | Computational chemistry | Physics-based molecular simulation + ML for drug design | $770M revenue (2024); multiple internal pipeline programs |

---

## B.6 Longevity & Aging Companies

| Company | Founded | Funding | Approach |
|---------|---------|---------|----------|
| **Altos Labs** | 2022 | $3B+ | Cellular rejuvenation / partial reprogramming; recruited Shinya Yamanaka, Juan Carlos Izpisua Belmonte, Jennifer Doudna as advisors |
| **Retro Biosciences** | 2021 | ~$180M (YC + Altman) | Autophagy, plasma-inspired therapies, partial reprogramming; backed by Sam Altman ($180M personal) |
| **NewLimit** | 2022 | ~$40M | Epigenetic reprogramming of immune cells; founded by Brian Armstrong (Coinbase CEO) |
| **Calico (Alphabet)** | 2013 | $1.5B+ | Fundamental biology of aging; AbbVie partnership ($2.5B); secretive, limited publications |
| **Unity Biotechnology** | 2016 | Public | Senolytics (clearing senescent cells); UBX1325 for ophthalmology |
| **Loyal** | 2019 | ~$125M | Longevity for dogs (LOY-002, LOY-001); large dog lifespan extension as pathway to human aging drugs |
| **BioAge Labs** | 2015 | Public | Azelaprag (obesity/muscle); human aging cohort data + AI for target discovery |

---

## B.7 Neurotech & Brain-Computer Interfaces

| Company | Focus | Stage |
|---------|-------|-------|
| **Neuralink** | Invasive BCI (N1 implant, 1024 electrodes) | First human implant 2024; "Telepathy" for ALS/paralysis patients |
| **Synchron** | Endovascular BCI (Stentrode) | FDA IDE; no open brain surgery required; mounted via blood vessels |
| **Precision Neuroscience** | High-density cortical array (Layer 7) | First human studies; 1,024+ electrodes; thin-film, minimally invasive |
| **Blackrock Neurotech** | Utah array (gold standard invasive BCI) | 40+ human implantations; most clinical BCI experience |
| **Kernel** | Non-invasive neuroimaging (Flow headset, TD-fNIRS) | Commercial; time-domain fNIRS for brain function measurement |

---

*This appendix reflects companies as of early 2026. Biotech moves fast — acquisitions, failures, and breakthroughs will reshape this landscape continuously. Use this as a starting map, not a permanent territory.*
